The rise of transformative cell and gene therapies presents important ethical questions on topics including pricing/value, global access, and germline gene editing. ARM believes that proactive engagement with a diverse range of stakeholders, from bioethicists to patients, religious leaders to policy experts, is essential to public support and the success of the field. ARM’s Ethics & Society project convenes stakeholders to explore the implications of this innovative technology, build trust with the public, and develop practical solutions.
ARM, the American Society for Gene and Cell Therapy, and the International Society for Cell & Gene Therapy released a joint declaration calling for a 10-year international moratorium on heritable human genome editing.
Cell and gene therapy has often made headlines due to its different reimbursement model, but the value of this medicine is often overlooked.
In 2024, ARM piloted value frameworks for gene therapy and CAR-T cell therapy, highlighting their unique benefits to society.
ARM is facilitating ongoing exchanges on the ethics of cell and gene therapy with stakeholders, including faith leaders, patient groups, bioethicists, and policymakers, to gather diverse perspectives and outline areas of common interest.
For example, ARM has been holding annual meetings with the Vatican’s Pontifical Academy of Life to exchange views with religious leaders on cell and gene therapy.
To learn more about ARM’s work on addressing ethical questions in cell and gene therapy, contact Adam Wolf at [email protected].
Sign up for ARM’s weekly newsletter on sector news and alerts for events, reports, and other engagement opportunities.
